Synopsis: Shares of Panacea Biotec Ltd gained in Wednesday’s session after the corporate acquired an award notification from the Pan American Well being Group (PAHO), the Regional Workplace of the World Well being Group (WHO), for the availability of vaccines value Rs. 41 crore over 2026-2027.
A small-cap pharmaceutical inventory noticed shopping for curiosity in at present’s commerce after securing a recent worldwide vaccine provide award, strengthening its export pipeline and order visibility.
Panacea Biotec Ltd, with a market capitalisation of Rs. 2,449.42 crore, opened at Rs. 407.05 on the BSE in opposition to its earlier shut of Rs. 396.40. The inventory touched an intraday excessive of Rs. 407.05, marking a rise of two.69 % from the earlier shut.
What’s the Information?
Panacea Biotec Ltd introduced that it has acquired an award notification from the Pan American Well being Group (PAHO), the Regional Workplace of the World Well being Group, below a long-term settlement for the availability of Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae kind B (DTP-HepB-Hib) Vaccine (Pentavalent) – Liquid (single dose), branded as Easyfive-TT.
Easyfive-TT is a five-in-one vaccine administered to infants and younger youngsters. It affords safety in opposition to 5 critical illnesses, Diphtheria, Haemophilus influenzae kind b, Hepatitis B, Pertussis, and Tetanus, by strengthening the immune system and stimulating the physique to supply protecting antibodies in opposition to these infections.
The overall award is valued at roughly USD 4.75 million (round Rs. 41 crore) for the availability of the Easyfive-TT vaccine throughout calendar years 2026 and 2027. The vaccine might be provided to PAHO as per their necessities below the long-term association.
Monetary Snapshot – Q1FY26
Quarter-on-Quarter (QoQ): In Q1FY26, Panacea Biotec posted sturdy sequential enchancment in efficiency. Gross sales rose from Rs. 132.53 crore in Q4FY25 to Rs. 166.70 crore, registering a rise of 25.8 %. Working loss narrowed sharply from Rs. 26.88 crore to Rs. 1.18 crore. Revenue earlier than tax turned optimistic, bettering from a marginal lack of Rs. 0.04 crore to a revenue of Rs. 6.56 crore. Internet revenue additionally rose from a lack of Rs. 1.99 crore to a revenue of Rs. 3.96 crore.
Yr-on-Yr (YoY): On an annual comparability, gross sales grew from Rs. 115.72 crore in Q1FY25 to Rs. 166.70 crore in Q1FY26, marking a 44 % enhance. Working loss diminished considerably from Rs. 13.99 crore to Rs. 1.18 crore. Revenue earlier than tax improved from a lack of Rs. 17.05 crore to a revenue of Rs. 6.56 crore, whereas web revenue rose from a lack of Rs. 15.88 crore to a revenue of Rs. 3.96 crore.
Concerning the Firm
Panacea Biotec Ltd is certainly one of India’s main research-driven biotechnology firms engaged within the analysis, improvement, manufacturing, and advertising and marketing of vaccines and pharmaceutical formulations. The corporate provides its merchandise throughout India and international markets, catering to each personal and institutional healthcare segments.
Written by Manan Gangwar
Disclaimer
The views and funding suggestions expressed by funding consultants/broking homes/score companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a danger of economic losses. Traders should due to this fact train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the writer usually are not chargeable for any losses triggered because of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
